News
EXEL
23.43
+2.06%
0.47
Exelixis Buy Rating Affirmed on Q2 Outperformance and Positive Litigation Outlook
TipRanks · 1d ago
Are Exelixis, Inc.'s (NASDAQ:EXEL) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Exelixis's (NASDAQ:EXEL) return on equity is lower than its industry average. The company has a 9.6% ROE, but its net income has declined by 26% over the last five years. Exelix is expected to grow its earnings in the next year. The ROE is a good indicator of a company's ability to reinvest and grow its profits. It has declined 5.3% in the past three months. ExelIXis has a high ROE but the company has no earnings growth to show for it.
Simply Wall St · 2d ago
Press Release: Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
Dow Jones · 3d ago
Weekly Report: what happened at EXEL last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at EXEL last week (0708-0712)?
Weekly Report · 07/15 09:01
September 20th Options Now Available For Exelixis (EXEL)
NASDAQ · 07/12 14:39
Morgan Stanley Sticks to Their Hold Rating for Exelixis (EXEL)
TipRanks · 07/12 12:27
Weekly Report: what happened at EXEL last week (0701-0705)?
Weekly Report · 07/08 09:01
With 74% ownership, Exelixis, Inc. (NASDAQ:EXEL) boasts of strong institutional backing
A total of 15 investors have a majority stake in Exelixis, Inc. (NASDAQ:EXEL) with 51% of the company. Institutional investors own over 50% of ExelIXis. The company is owned by a group of 15 major shareholders. The majority of the shares are owned by institutions, with the largest holding of 74% of company. Exelxis has a history of growth but there's more to the story than just the share price. Check out the insider trading activities of Exerixis and its CEO.
Simply Wall St · 07/04 10:07
Ipsen Expands Exelixis Collaboration For Cabometyx In Advanced Neuroendocrine Tumors
NASDAQ · 07/02 05:39
Weekly Report: what happened at EXEL last week (0624-0628)?
Weekly Report · 07/01 09:01
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
NASDAQ · 06/25 10:20
Weekly Report: what happened at EXEL last week (0617-0621)?
Weekly Report · 06/24 09:01
Weekly Report: what happened at EXEL last week (0610-0614)?
Weekly Report · 06/17 09:01
If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity
Exelixis has grown its earnings per share growth by 50% per year, over the last three years. The company has a large amount of wealth invested in the company, currently valued at US$111m. ExelIXis is a company that generates revenue and profits, and is growing at a high rate. Insiders hold a large percentage of the company and are keen to align their interests with shareholders. The firm is worth adding to your watchlist of companies with strong insider holdings.
Simply Wall St · 06/14 10:27
Weekly Report: what happened at EXEL last week (0603-0607)?
Weekly Report · 06/10 09:01
Exelixis Shareholders Vote on Governance and Incentives
TipRanks · 06/03 21:56
Exelixis Breaks Above 200-Day Moving Average - Bullish for EXEL
NASDAQ · 06/03 15:38
Weekly Report: what happened at EXEL last week (0527-0531)?
Weekly Report · 06/03 09:01
Friday 5/31 Insider Buying Report: EXEL, BHVN
NASDAQ · 05/31 14:59
More
Webull provides a variety of real-time EXEL stock news. You can receive the latest news about Exelixis Inc through multiple platforms. This information may help you make smarter investment decisions.
About EXEL
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.